Skip Ribbon Commands
Skip to main content

Hepato-pancreato-biliary (HPB) Cancers

DSO hosts the multi-disciplinary Comprehensive Liver Cancer Clinic (CLCC) at NCCS comprising HPB surgeons, medical oncologists, radiation oncologist, nuclear medicine physicians, interventional radiologists, oncologic diagnostic radiologists, pathologists and nurse practitioners. The CLCC manages the whole spectrum of patients with HPB malignancies and multi-disciplinary case discussions are conducted twice a week. The HPB surgery team is heavily involved in clinically-driven cutting-edge translational and clinical studies that aim to interrogate the molecular and mechanistic basis of liver cancer, improve patient diagnosis and prognosis and develop novel therapies for HPB diseases by bringing discoveries from the bench to the bedside that can be translated to the next effective therapy. 

The HPB discipline has vast experiences in conducting multicentre clinical trials and has spearheaded numerous investigator-initiated multicentre HCC clinical trials leveraging on the Asia-Pacific Hepatocellular Carcinoma (AHCC) trials group which has over 40 sites in 17 different countries and has completed 6 multi-centre prospective studies. 

The team also coordinates the NMRC Flagship Translational and Clinical Research Program in Liver Cancer. The program conducts the world’s first prospective multi-center clinico-omics (genomics, immunomics, metabolomics) HCC study with PDX and PDP components. This prospective study is carried out in collaboration with major research institutes in Singapore (NUS/CSI, IMCB, CIS, NTU) and internationally.